US OptionsDetailed Quotes

BMRN250516C50000

Watchlist

9.60
0.000.00%

15min DelayClose Apr 29 16:00 ET

0.00High0.00Low

Biomarin Pharmaceutical Stock Discussion

Moomoo AI

Mar 25, 2024 20:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

Moomoo AI

Mar 7, 2024 21:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Moomoo AI

Feb 8, 2024 22:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Jan 18, 2024 20:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 22, 2023 00:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts

Moomoo AI

Dec 6, 2023 20:57

The report is neutral to bearish due to lack of recent insider buying and considerable selling action, indicating potential low confidence. High insider ownership might align incentives with other shareholders.

Possible Bearish Signals With BioMarin Pharmaceutical Insiders Disposing Stock

SOARMAN

Nov 8, 2023 01:47

Stocks making the biggest midday moves

Here are some of the names moving in midday trading:
$Datadog (DDOG.US)$
— Shares rallied more than 30% after the cloud company reported a third-quarter earnings and revenue beat before the bell. Datadog’s guidance for both earnings per share and revenue for the fourth quarter and the full year also exceeded expectations.
$Biomarin Pharmaceutical (BMRN.US)$
l — The pharma stock gained 11.4% after activist investor Elliott Investment Management built a stake i...